Pharmaceutical Executive-12-06-2006

Pharmaceutical Executive

December 06, 2006

Pfizer, Novartis--and even Merck--are putting the past behind them, and moving forward with COX-2 innovation.

Pharmaceutical Executive

December 06, 2006

Possible sale of medical nutrition unit would not mark change in business model for the diversified drug maker.

Pharmaceutical Executive

December 06, 2006

Pfizer's torcetrapib blow shifts cost-cutting measures into overdrive, causing all of industry to reevaluate staffing, marketing spend, and the viability of a potential cardiovascular breakthrough.